Read more
Baxdrostat vs. Spironolactone: A New Mechanism Meets an Old Bargain - THE $5-BILLION QUESTION
IV Iron in Oncology: Time to Rethink Your Default
When the New β-Lactam/β-Lactamase Inhibitors Aren’t Enough
Asundexian for Secondary Stroke Prevention OCEANIC-STROKE — A Three-Lens Critical Appraisal
OCEANIC-STROKE met its primary endpoint with a 26% relative reduction in ischemic stroke and no excess major bleeding — but the prespecified hierarchy broke at the 90-day endpoint. A statistician, a neurologist, and a researcher walk into a journal club. Here's what they each see.